Yuki Kojima

ORCID

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 11

Top Venues

NPJ breast cancer

Cancers

Diagnostics (Basel, Switzerland)

BMC cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Masaki Uchihara, Akiyo Tanabe, Yuki Kojima, Tatsunori Shimoi, Akiko Miyagi Maeshima, Kotaro Umamoto, Akihiko Shimomura, Chikako Shimizu, Yuto Yamazaki, Eijiro Nakamura, Yoshiyuki Matsui, Nobuyuki Takemura, Hideyo Miyazaki, Kazuki Sudo, Kan Yonemori, Hiroshi Kajio
Immunohistochemical Profiling of SSTR2 and HIF-2α with the Tumor Microenvironment in Pheochromocytoma and Paraganglioma. Cancers 16 (12) (2024)
Masaki Uchihara, Akiyo Tanabe, Yuki Kojima, Tatsunori Shimoi, Akiko Miyagi Maeshima, Kotaro Umamoto, Akihiko Shimomura, Chikako Shimizu, Yuto Yamazaki, Eijiro Nakamura, Yoshiyuki Matsui, Nobuyuki Takemura, Hideyo Miyazaki, Kazuki Sudo, Kan Yonemori, Hiroshi Kajio
Immunohistochemical Profiling of SSTR2 and HIF-2α with the Tumor Microenvironment in Pheochromocytoma and Paraganglioma. Cancers 16 (12) (2024)
Rui Kitadai, Tatsunori Shimoi, Shu Yazaki, Hitomi Sumiyoshi Okuma, Mai Hoshino, Munehiro Ito, Ayumi Saito, Shosuke Kita, Yuki Kojima, Tadaaki Nishikawa, Kazuki Sudo, Emi Noguchi, Yasuhiro Fujiwara, Masayuki Yoshida, Kan Yonemori
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine. Breast cancer (Tokyo, Japan) (2024)
Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai, Naohito Yamamoto, Chi-Feng Chung, Yen-Shen Lu, Dwan-Ying Chang, Joohyuk Sohn, Gun Min Kim, Kyung-Hun Lee, Soo-Chin Lee, Tsutomu Iwasa, Hiroji Iwata, Kenichi Watanabe, Kyung Hae Jung, Yuko Tanabe, Seok Yun Kang, Hiroyuki Yasojima, Kenjiro Aogi, Eriko Tokunaga, Sung Hoon Sim, Yoon Sim Yap, Koji Matsumoto, Ling-Ming Tseng, Yoshiko Umeyama, Kazuki Sudo, Yuki Kojima, Tomomi Hata, Aya Kuchiba, Taro Shibata, Kenichi Nakamura, Yasuhiro Fujiwara, Kenji Tamura, Kan Yonemori
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer. NPJ breast cancer 10 (1) (2024)
Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai, Naohito Yamamoto, Chi-Feng Chung, Yen-Shen Lu, Dwan-Ying Chang, Joohyuk Sohn, Gun Min Kim, Kyung-Hun Lee, Soo-Chin Lee, Tsutomu Iwasa, Hiroji Iwata, Kenichi Watanabe, Kyung Hae Jung, Yuko Tanabe, Seok Yun Kang, Hiroyuki Yasojima, Kenjiro Aogi, Eriko Tokunaga, Sung Hoon Sim, Yoon Sim Yap, Koji Matsumoto, Ling-Ming Tseng, Yoshiko Umeyama, Kazuki Sudo, Yuki Kojima, Tomomi Hata, Aya Kuchiba, Taro Shibata, Kenichi Nakamura, Yasuhiro Fujiwara, Kenji Tamura, Kan Yonemori
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer. NPJ breast cancer 10 (1) (2024)
Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai, Naohito Yamamoto, Chi-Feng Chung, Yen-Shen Lu, Dwan-Ying Chang, Joohyuk Sohn, Gun Min Kim, Kyung-Hun Lee, Soo-Chin Lee, Tsutomu Iwasa, Hiroji Iwata, Kenichi Watanabe, Kyung Hae Jung, Yuko Tanabe, Seok Yun Kang, Hiroyuki Yasojima, Kenjiro Aogi, Eriko Tokunaga, Sung Hoon Sim, Yoon Sim Yap, Koji Matsumoto, Ling-Ming Tseng, Yoshiko Umeyama, Kazuki Sudo, Yuki Kojima, Tomomi Hata, Aya Kuchiba, Taro Shibata, Kenichi Nakamura, Yasuhiro Fujiwara, Kenji Tamura, Kan Yonemori
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer. NPJ breast cancer 10 (1) (2024)
Takafumi Koyama, Toshio Shimizu, Yuki Kojima, Kazuki Sudo, Hitomi Sumiyoshi Okuma, Tatsunori Shimoi, Hitotshi Ichikawa, Shinji Kohsaka, Ryo Sadachi, Akihiro Hirakawa, Akihiko Yoshida, Reiko Makihara Ando, Toshihide Ueno, Mitsuru Yanagaki, Naoko Matsui, Kenichi Nakamura, Noboru Yamamoto, Kan Yonemori
Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study. Cancer discovery (2023)
Yuki Kojima, Emi Noguchi, Tomomi Yoshino, Shigehiro Yagishita, Shu Yazaki, Hitomi S Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Tatsunori Shimoi, Ayaka Kazama, Hiroshi Terasaki, Sachiro Asano, Yasuhiro Fujiwara, Akinobu Hamada, Kenji Tamura, Kan Yonemori
Development of a Detection System for ESR1 Mutations in Circulating Tumour DNA Using PNA-LNA-Mediated PCR Clamping. Diagnostics (Basel, Switzerland) 13 (12) (2023)
Yuki Kojima, Emi Noguchi, Tomomi Yoshino, Shigehiro Yagishita, Shu Yazaki, Hitomi S Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Tatsunori Shimoi, Ayaka Kazama, Hiroshi Terasaki, Sachiro Asano, Yasuhiro Fujiwara, Akinobu Hamada, Kenji Tamura, Kan Yonemori
Development of a Detection System for ESR1 Mutations in Circulating Tumour DNA Using PNA-LNA-Mediated PCR Clamping. Diagnostics (Basel, Switzerland) 13 (12) (2023)
Shigemasa Takamizawa, Shu Yazaki, Yuki Kojima, Hiroshi Yoshida, Rui Kitadai, Tadaaki Nishikawa, Tatsunori Shimoi, Kazuki Sudo, Hitomi Sumiyoshi Okuma, Maki Tanioka, Emi Noguchi, Masaya Uno, Mitsuya Ishikawa, Tomoyasu Kato, Yasuhiro Fujiwara, Kan Yonemori
High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective study. BMC cancer 22 (1) (2022)
Shu Yazaki, Yuki Kojima, Hiroshi Yoshida, Shigemasa Takamizawa, Rui Kitadai, Tadaaki Nishikawa, Tatsunori Shimoi, Kazuki Sudo, Ayumi Saito, Hitomi Sumiyoshi Okuma, Maki Tanioka, Emi Noguchi, Masaya Uno, Mitsuya Ishikawa, Tomoyasu Kato, Yasuhiro Fujiwara, Yuichiro Ohe, Kan Yonemori
High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer. Journal of gynecologic oncology 33 (6) (2022)

Yuki Kojima.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yuki Kojima